Low amniotic fluid

Disease Description (Causes and Symptoms)

• Summary: Myeloproliferative neoplasms (MPNs) are a group of chronic bone marrow diseases in which hematopoietic cells (red blood cells, white blood cells, and platelets) proliferate abnormally. Major subtypes include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myeloid leukemia (CML).
• Causes/Pathophysiology: In most cases, mutations in signaling genes of bone marrow hematopoietic cells (mainly JAK2 V617F, CALR, MPL, etc.) cause hematopoietic cells to proliferate autonomously. This can lead to increased peripheral blood cell counts or fibrosis of the bone marrow structure.
• Main symptoms:
  • Thrombosis (occlusion, cerebral infarction, myocardial infarction, etc.) or peripheral ischemia (coldness or pain in the hands and feet)
  • Bleeding tendency (bruising, gum bleeding, etc.) — particularly with platelet dysfunction or a very high platelet count
  • Splenomegaly (abdominal distension, discomfort in the left upper abdomen)
  • Symptoms of anemia (fatigue, shortness of breath)
  • Flushing, itching (especially pruritus occurring after a hot bath or shower), headache, and dizziness
• Diagnostic tests (briefly): Peripheral blood tests (complete blood cell counts), peripheral blood smear (tear‑drop RBCs, immature red and white blood cells), bone marrow examination (biopsy), genetic tests (JAK2/CALR/MPL; BCR‑ABL when CML is suspected), red blood cell mass measurement and EPO (for differentiating polycythemia vera).

Treatment (Standard Treatment, Medications, Procedures, Lifestyle Management, and Precautions)

• Treatment principles: Individualized treatment is provided by classifying risk according to disease subtype, age, history of thrombosis, blood cell count levels, and presence or absence of symptoms.
• Polycythemia vera (PV)
  • Blood removal (phlebotomy): Target hematocrit is <45% in men and <42% in women.
  • Low-dose aspirin (thrombosis prevention): Generally 81–100 mg/day (determined after assessing bleeding risk).
  • High-risk patients (older age or a history of thrombosis): Add cytoreductive therapy (hydroxyurea or interferon).
  • Symptom control (such as itching): Antihistamines, topical treatments, etc.
• Essential thrombocythemia (ET)
  • Low risk (younger age and no symptoms): Observation (regular testing).
  • High risk of thrombosis (older age, history of thrombosis, or very high platelet count): Low-dose aspirin and cytoreductive agents (hydroxyurea, interferon-α, anagrelide, etc.).
  • Precaution: With an extremely high platelet count, acquired von Willebrand syndrome can increase the risk of bleeding — caution is needed regarding rapid correction of the platelet count and the use of anticoagulants during treatment.
• Primary myelofibrosis (PMF)
  • Asymptomatic and low risk: Observation.
  • Symptoms (anemia, splenomegaly, or constitutional symptoms) or intermediate/high risk: Symptom-relieving treatment (transfusions, erythropoietin/steroids, etc. for anemia); JAK inhibitors (ruxolitinib) may be used for splenic and constitutional symptoms.
  • Younger patients and those eligible for transplantation: Consider curative treatment with allogeneic hematopoietic stem cell transplantation (the only potential curative treatment in high-risk patients).
• Chronic myeloid leukemia (CML)
  • When BCR‑ABL-positive, standard treatment is tyrosine kinase inhibitors (TKIs, such as imatinib, dasatinib, and nilotinib).
• Prevention and management of complications
  • Thrombosis prevention (maintain hydration, do not smoke, consider antithrombotic treatment during prolonged bed rest) and monitoring for signs of bleeding.
  • Be aware of the possibility of progression to leukemia (acute myeloid leukemia) (the risk varies according to subtype and genetic mutation: approximately 10–20%/10 years for PMF, 2–3%/10 years for PV, and <1%/10 years for ET have been reported).
• Lifestyle management (general recommendations)
  • Do not smoke, exercise regularly (manage cardiovascular risk factors), drink sufficient fluids, and avoid excessive alcohol and dehydration.
  • Immediate emergency evaluation is necessary if bleeding or thrombotic symptoms occur.
  • For women, treatment may need to be changed when planning a pregnancy (for example, interferon is preferred, and some drugs may cause congenital abnormalities) — prior consultation with a doctor is essential.

Checklist Before an Outpatient Visit (Including What to Bring and Example Questions)

• Items to bring (documents/information)
  • Recent blood test results (including CBC), and bone marrow examination and genetic test results (if available)
  • A list of all medications and supplements currently being taken (including dose and frequency)
  • A summary of medical history, including previous thrombosis or bleeding, transfusions, surgeries, and pregnancies
  • Symptom records: sensation of splenomegaly (left upper abdominal distension), itching (when it occurs and in what situations it is worse), weakness or shortness of breath, newly developed bruising or bleeding, or changes in skin color, etc.
• Things to check before the outpatient visit
  • Recent weight changes, fever, and whether there are any symptoms of infection
  • Symptoms suspicious for thrombosis (sudden limb pain or numbness, shortness of breath, chest pain, speech abnormalities, etc.)
  • Check whether you are taking anticoagulants or antiplatelet agents
• Example questions (questions to prepare in advance for the doctor)
  • “My recent test results show these blood cell counts. Are they at a level that requires treatment?”
  • “Could the medications I am taking (for example, blood pressure medication or aspirin) cause problems with my current treatment?”

Examples of General Questions to Ask the Doctor

• What are the main side effects and their frequency for this medication (for example, hydroxyurea, interferon, ruxolitinib, or imatinib)? How should they be managed if they occur?
• How is the risk of my disease (risk of thrombosis, bleeding, or transformation to leukemia) assessed, and what is the prognosis?
• I am planning a pregnancy. How should my current treatment be adjusted? Which medications are contraindicated during contraception or pregnancy?
• Are there any special precautions I should take regarding lifestyle habits (exercise, diet, and alcohol consumption)?

Examples of Disease-Specific Questions

• (For patients with PV) “What is my target hematocrit, and how often should I undergo phlebotomy? How should I prepare to reduce symptoms such as dizziness during phlebotomy?”
• (For patients with ET) “My platelet count is very high (for example, 1 million). How can the risks of bleeding and thrombosis be balanced? Is a von Willebrand test or any additional testing necessary?”